Cargando…
Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma
INTRODUCTION: Intrahepatic cholangiocarcinoma (ICC) is a rare hepatobiliary cancer characterized by a poor prognosis and a limited response to conventional therapies. Currently chemotherapy is the only therapeutic option for patients with Stage IV ICC. Due to the poor response rate, there is an urge...
Autores principales: | Sabbatino, Francesco, Liguori, Luigi, Malapelle, Umberto, Schiavi, Francesca, Tortora, Vincenzo, Conti, Valeria, Filippelli, Amelia, Tortora, Giampaolo, Ferrone, Cristina R., Pepe, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728995/ https://www.ncbi.nlm.nih.gov/pubmed/33330039 http://dx.doi.org/10.3389/fonc.2020.567289 |
Ejemplares similares
-
Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients
por: Sabbatino, Francesco, et al.
Publicado: (2021) -
Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma
por: Andrici, Juliana, et al.
Publicado: (2016) -
Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
por: Marcus, Rebecca, et al.
Publicado: (2021) -
Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022) -
BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways
por: Chen, Xu-Xiao, et al.
Publicado: (2018)